$2.160
-0.149 (-6.90%)At close
XRTX Comparative Benchmarking
In the context of the broader market, XRTX competes directly with industry leaders such as GELS and PCSA. With a market capitalization of $4.43M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against GELS's N/A and PCSA's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.
XORTX Therapeutics Inc Financial Performance
XORTX has shown mixed financial performance, with a recent net income of -808472 USD in Q1 2026 and a forward P/E of 0.9621, suggesting potential for recovery but also indicating ongoing losses.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.